ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting

Rhea-AI Summary

ProSomnus, Inc. (NASDAQ: OSA) has announced the publication of four abstracts in the Journal of Dental Sleep Medicine, which will be presented at the 2023 AADSM Annual Meeting in Philadelphia from May 19-21. The abstracts cover significant studies, including a comparison of efficacy between precision oral appliance therapy and traditional methods, and an analysis of adverse events related to various sleep apnea treatments.

The studies highlight ProSomnus’s position as a leader in precision medical devices for Obstructive Sleep Apnea (OSA), a condition affecting over 74 million people in North America. The company's FDA-cleared devices are recognized for being less invasive and more comfortable than CPAP therapy, making them a patient-preferred option.

Positive

• Four abstracts published in the Journal of Dental Sleep Medicine strengthen ProSomnus's scientific credibility.
• ProSomnus's devices are the most prescribed Precision Oral Appliance Therapy in the U.S., with over 200,000 delivered.
• FDA-cleared devices are often covered by medical insurance and Medicare, enhancing market penetration.

Negative

• None.

Study results to be presented in oral and poster presentations at 2023 American Academy of Dental Sleep Medicine Annual Meeting

PLEASANTON, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the publication of four abstracts in the Journal of Dental Sleep Medicine. The abstracts can be found at https://aadsm.org/journal/abstracts_issue_102.php.

These data will be presented in oral and poster presentations at the 2023 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, being held from May 19-21 in Philadelphia, Pennsylvania.

Titles of the accepted abstract presentations at AADSM are as follows:

Title	Precision Vs. Traditional Oral Appliance Therapy: a Comparison of Therapeutic Efficacy
Abstract Number	006
Title	Comparison of Clinical Effectiveness And Patients’ Preference for Two Non-invasive Treatment Options for Patients Diagnosed with Moderate to Severe Obstructive Sleep Apnea: The FLOSAT Study
Abstract Number	008
Title	OAT Device Designs are Not the Same When It Comes to FDA Adverse Event Reports
Abstract Number	011
Title	Adverse Event Reports for Continuous Positive Airway Pressure, Hypoglossal Nerve Stimulation and Oral Appliance Therapy Devices: an FDA MAUDE Database Analysis
Abstract Number	012

About ProSomnus
ProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient-preferred treatment for patients suffering from Obstructive Sleep Apnea (OSA). ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus’s patented, FDA-cleared devices are a less invasive and more comfortable alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to effective and patient-preferred outcomes. A growing body of research, including studies published by the Journal of Clinical Sleep Medicine and Military Medicine, suggests ProSomnus’s Precision OAT devices are an effective treatment for mild to moderate OSA. Additional clinical research has shown that ProSomnus’s Precision OAT devices mitigate many of the side effects associated with alternative treatments and improve economics for payers and providers. With more than 200,000 devices delivered, ProSomnus’s devices are the most prescribed Precision OAT in the U.S. ProSomnus’s FDA-cleared devices are authorized by the Department of Defense and the U.S. Army, and are often covered by medical insurance, Medicare, and social health programs in key international markets. To learn more, visit www.ProSomnus.com.

Investor Contact
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media Contact
Elizabeth Coleman
ICR Westwicke
Phone: +1.203.682.4783
Email: Elizabeth.Coleman@westwicke.com

FAQ

What are the key findings from ProSomnus's abstracts presented at the AADSM Annual Meeting?

ProSomnus's abstracts focus on the efficacy of precision oral appliance therapy compared to traditional treatments and analyze adverse events associated with various devices.

When is the 2023 AADSM Annual Meeting where ProSomnus's results will be presented?

The meeting will take place from May 19-21, 2023, in Philadelphia, Pennsylvania.

What is the significance of ProSomnus's research on obstructive sleep apnea?

ProSomnus's research highlights important comparisons in treatment efficacy, positioning their devices as effective alternatives to CPAP therapy.

How does ProSomnus's device compare to CPAP therapy?

ProSomnus's precision oral appliance therapy is less invasive and generally more comfortable than CPAP, making it a preferred choice for patients.

What market does ProSomnus primarily serve?

ProSomnus primarily serves the North American market, targeting over 74 million individuals suffering from obstructive sleep apnea.